Association of antinuclear antibodies with the risk of intracranial arterial stenosis

Sun, Ying; Han, Qian; Hou, Xiao-He; Peng, Xiangyu; Tong, Lin; Zheng, Xu; Yu, Jin‐Tai; Tan, Lan

doi:10.18632/aging.102685

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several new associations have been revealed between the presence of ANAs and diseases which are not generally considered to be related to autoimmunity: for example, ANAs have been found in idiopathic epilepsy [ 129 ], ischemic brain disease [ 130 ], interstitial lung diseases [ 131 ], schizophrenia [ 132 ], and other ailments. According to O.V.…”

Section: Ana: Detection Polyspecificity and Relation To Ad Pathomentioning

confidence: 99%

Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease

et al. 2021

View full text Add to dashboard Cite

The incidence of autoimmune diseases is increasing. Antinuclear antibody (ANA) testing is a critical tool for their diagnosis. However, ANA prevalence in healthy persons has increased over the last decades, especially among young people. ANA in health occurs in low concentrations, with a prevalence up to 50% in some populations, which demands a cutoff revision. This review deals with the origin and probable physiological or compensatory function of ANA in health, according to the concept of immunological clearance, theory of autoimmune regulation of cell functions, and the concept of functional autoantibodies. Considering ANA titers ≤1:320 as a serological marker of autoimmune diseases seems inappropriate. The role of anti-DFS70/LEDGFp75 autoantibodies is highlighted as a possible anti-risk biomarker for autoimmune rheumatic disorders. ANA prevalence in health is different in various regions due to several underlying causes discussed in the review, all influencing additive combinations according to the concept of the mosaic of autoimmunity. Not only are titers, but also HEp-2 IFA) staining patterns, such as AC-2, important. Accepting autoantibodies as a kind of bioregulator, not only the upper, but also the lower borders of their normal range should be determined; not only their excess, but also a lack of them or “autoimmunodeficiency” could be the reason for disorders.

show abstract

Section: Ana: Detection Polyspecificity and Relation To Ad Pathomentioning

confidence: 99%

Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In SLE patients with ischemic stroke, the presence of antinuclear antibody (ANA) was associated with intracranial arterial stenosis, 25 via mechanisms of dysregulation of endothelial cells. 26 Anti-double-stranded DNA (anti-dsDNA) antibodies have been also with an inflammatory burden in the brain of SLE stroke patients with increased levels of inflammatory markers such as IL-1β and IL-6.…”

Section: Diagnostic Toolsmentioning

confidence: 99%

Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch

Hasbani

Uthman

2023

Lupus

View full text Add to dashboard Cite

Cerebrovascular accidents (CVAs) or strokes are part of the common thrombotic manifestations of Systemic Lupus Erythematosus (SLEs) and Antiphospholipid syndrome (APS). Such neurological thrombotic events tend to occur in patients with SLE at a higher frequency when Antiphospholipid antibodies (aPLs) are present, and tend to involve the large cerebral vessels. The mechanism of stroke in SLE can be driven by complement deposition and neuroinflammation involving the blood–brain barrier although the traditional cardiovascular risk factors remain major contributing factors. Primary prevention with antiplatelet therapy and disease activity controlling agent is the basis of the management. Anticoagulation via warfarin had been a tool for secondary prevention, especially in stroke recurrence, although the debate continues regarding the target international normalized ratio (INR). The presence of either of the three criteria antiphospholipid antibodies (aPLs) and certain non-criteria aPL can be an independent risk factor for stroke. The exact mechanism for the involvement of the large cerebral arteries, especially in lupus anticoagulant (LAC) positive cases, is still to be deciphered. The data on the role of non-criteria aPL remain very limited and heterogenous, but IgA antibodies against β2GPI and the D4/5 subunit as well as aPS/PT IgG might have a contribution. Anticoagulation with warfarin has been recommended although the optimal dosing or the utility of combination with antiplatelet agents is still unknown. Minimal data is available for direct oral anticoagulants (DOACs).

show abstract

Antiphospholipid antibodies as potential prognostic indicators of recurrent ischemic stroke

Geng,

Pan,

et al. 2024

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

Association of antinuclear antibodies with the risk of intracranial arterial stenosis

Cited by 4 publications

References 21 publications

Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease

Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease

Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch

Antiphospholipid antibodies as potential prognostic indicators of recurrent ischemic stroke

Contact Info

Product

Resources

About